Summary

The goals for the management of schizophrenia and schizoaffective disorders are to decrease severity and frequency of psychosis and associated mood symptoms while reducing the inherent risks of antipsychotic medications. Aripiprazole demonstrates agonist activity toward dopamine D2 and 5-HT1a receptors and antagonizes 5-HT2a receptors, sites that are associated with psychosis and mood disorders.